Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection

Conference Reports for NATAP

19th International Workshop on
Clinical Pharmacology of Antiviral Therapy
May 22, 2018
Baltimore, USA | Baltimore Marriott Inner Harbor


Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection

	Reported by Jules Levin 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22-24, 2018, Baltimore, Maryland Justin D. Lutz, Yongwu Shao, John Ling, Joseph M. Custodio, Hal Martin, Erin Quirk and Anita Mathias Gilead Sciences, Inc., Foster City, CA